GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lipum AB (OSTO:LIPUM) » Definitions » Inventory-to-Revenue

Lipum AB (OSTO:LIPUM) Inventory-to-Revenue : 0.00 (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Lipum AB Inventory-to-Revenue?

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Lipum AB's Average Total Inventories for the quarter that ended in Mar. 2024 was kr0.00 Mil. Lipum AB's Revenue for the three months ended in Mar. 2024 was kr0.00 Mil.

Lipum AB's Inventory-to-Revenue for the quarter that ended in Mar. 2024 stayed the same from Dec. 2023 (0.00) to Dec. 2023 (0.00)

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.


Lipum AB Inventory-to-Revenue Historical Data

The historical data trend for Lipum AB's Inventory-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lipum AB Inventory-to-Revenue Chart

Lipum AB Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Inventory-to-Revenue
- - - - -

Lipum AB Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Inventory-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Lipum AB's Inventory-to-Revenue

For the Biotechnology subindustry, Lipum AB's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lipum AB's Inventory-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lipum AB's Inventory-to-Revenue distribution charts can be found below:

* The bar in red indicates where Lipum AB's Inventory-to-Revenue falls into.



Lipum AB Inventory-to-Revenue Calculation

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Lipum AB's Inventory-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Inventory-to-Revenue (A: Dec. 2023 )
=Average Total Inventories / Revenue
=( (Total Inventories (A: Dec. 2022 ) + Total Inventories (A: Dec. 2023 )) / count ) / Revenue (A: Dec. 2023 )
=( (0 + 0) / 1 ) / 0
=0 / 0
=N/A

Lipum AB's Inventory-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Inventory-to-Revenue (Q: Mar. 2024 )
=Average Total Inventories / Revenue
=( (Total Inventories (Q: Dec. 2023 ) + Total Inventories (Q: Mar. 2024 )) / count ) / Revenue (Q: Mar. 2024 )
=( (0 + 0) / 1 ) / 0
=0 / 0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lipum AB  (OSTO:LIPUM) Inventory-to-Revenue Explanation

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.

Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.

More Related Terms:

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Lipum AB's Days Inventory for the three months ended in Mar. 2024 is calculated as:

Days Inventory=Average Total Inventories (Q: Mar. 2024 )/Cost of Goods Sold (Q: Mar. 2024 )*Days in Period
=0/0*365 / 4
=

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Lipum AB's Inventory Turnover for the quarter that ended in Mar. 2024 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Mar. 2024 ) / Average Total Inventories (Q: Mar. 2024 )
=0 / 0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lipum AB Inventory-to-Revenue Related Terms

Thank you for viewing the detailed overview of Lipum AB's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Lipum AB (OSTO:LIPUM) Business Description

Traded in Other Exchanges
N/A
Address
Tvistevagen 48 C, Umea, SWE, 907 36
Lipum AB is a clinical-stage biopharmaceutical company specializing in the discovery and development of a novel treatment for chronic inflammatory diseases. The candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule (BSSL) of the immune system. The development is supported by solid pre-clinical data for rheumatoid arthritis. Lipum also explores other inflammatory diseases with a high unmet medical need.

Lipum AB (OSTO:LIPUM) Headlines

No Headlines